文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

常温离体保存结合便携式器官养护系统肺装置用于双肺移植(INSPIRE):一项随机、开放标签、非劣效性3期研究

Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study.
PubMed 文献 · Lancet Respir Med · 2018-04-09
一句话结论INSPIRE试验达到主要有效性和安全性终点:OCS Lung常温离体保存组72小时内PGD3发生率17.7%低于冷静态保存组29.7%,但30天生存率OCS组95.7%低于对照组100%。

INSPIRE为随机、开放标签、非劣效性3期试验,纳入标准标准双肺移植候选者,供体年龄小于65岁且PaO2/FiO2大于300 mm Hg,1:1随机分入OCS Lung装置常温离体保存组或4°C冷静态保存组。主要复合有效性终点为移植后72小时内无PGD3且30天生存,非劣效界值4%;OCS组79.4% vs 对照组70.3%,非劣效成立(p=0.0038),优效性检验p=0.068。72小时内PGD3发生率OCS组17.7% vs 对照组29.7%(优效性p=0.015);30天生存率OCS组95.7% vs 对照组100%(p=0.0090),12个月生存率两组相似。主要安全性终点达标。作者认为虽无短期生存获益,但PGD3减少是否转化为更早恢复和长期结局改善需进一步研究。

要点

  • 标准标准双肺移植候选者中,OCS Lung常温离体保存组72小时内PGD3发生率为17.7%(25/141),低于冷静态保存组的29.7%(49/165),优效性检验p=0.015。
  • 主要复合有效性终点(72小时内无PGD3且30天生存)OCS组79.4%(112/141)vs 对照组70.3%(116/165),非劣效成立(p=0.0038),优效性检验p=0.068未达统计学显著。
  • 30天生存率OCS组95.7%(135/141)低于对照组100%(165/165),p=0.0090;12个月生存率OCS组89.4% vs 对照组88.1%。
  • 主要安全性终点达标:OCS组肺移植物相关严重不良事件平均0.23起 vs 对照组0.28起,非劣效检验p=0.020。
  • 作者认为虽无短期生存获益,但72小时内PGD3发生率降低是否可转化为更早恢复和长期结局改善,需进一步研究。

适用人群与场景

  • 受者为年龄18岁及以上、注册为标准标准初次双肺移植候选者。
  • 供者为年龄小于65岁、动脉血氧分压与吸入氧分数比值大于300 mm Hg者。

诊断标准与关键阈值

  • 主要复合有效性终点:移植后72小时内无PGD3且30天生存,非劣效界值4%。
  • 主要安全性终点:移植后30天内肺移植物相关严重不良事件的平均数量。

处置流程与药物剂量

  • 供肺随机分配至OCS Lung装置常温离体保存(OCS组)或4°C冷静态保存(对照组)。
  • 移植受者按1:1随机分组,采用置换区组法,按中心分层。

研究设计与关键结果

  • 随机、开放标签、非劣效性3期试验(INSPIRE),2011年11月17日至2014年11月24日随机370例,320例(86%)接受移植(OCS组151例,对照组169例),随访于2016年11月24日完成。
  • 主要复合有效性终点(符合方案人群):OCS组112/141例(79.4%,95%CI 71.8-85.8)vs 对照组116/165例(70.3%,95%CI 62.7-77.2),非劣效点估计-9.1%(95%CI -∞至-1.0),非劣效检验p=0.0038,优效性检验p=0.068。
  • 移植后72小时内PGD3发生率:OCS组25/141例(17.7%,95%CI 11.8-25.1)vs 对照组49/165例(29.7%,95%CI 22.8-37.3),优效性检验p=0.015。
  • 移植后30天患者生存率:OCS组135/141例(95.7%,95%CI 91.0-98.4)vs 对照组165/165例(100%,95%CI 97.8-100.0),p=0.0090。
  • 移植后12个月生存率:OCS组126/141例(89.4%,95%CI 83.1-93.9)vs 对照组146/165例(88.1%,95%CI 81.8-92.8)。
  • 主要安全性终点:OCS组肺移植物相关严重不良事件平均0.23起 vs 对照组0.28起,点估计-0.045%(95%CI -∞至0.047),非劣效检验p=0.020。
  • 意向治疗人群中30天及住院期间死亡原因:肺移植物衰竭或肺部感染(OCS组2例 vs 对照组7例)、心脏原因(4例 vs 1例)、血管或卒中(3例 vs 0例)、代谢性昏迷(0例 vs 2例)、全身性脓毒症(0例 vs 1例)。

证据类型、等级与局限

  • 证据类型:随机、开放标签、非劣效性3期试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,虽未报告短期生存获益,但需进一步研究以明确移植后72小时内PGD3发生率降低是否可转化为更早恢复和长期结局改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage.

METHODS: In this non-inferiority, randomised, controlled, open-label, phase 3 trial (INSPIRE) recipients were aged 18 years or older and were registered as standard criteria primary double lung transplant candidates. Eligible donors were younger than 65 years old with a ratio of partial pressure of oxygen in arterial blood to the fraction of inspired oxygen of more than 300 mm Hg. Transplant recipients were randomly assigned (1:1) with permuted blocks, stratified by centre, to receive standard criteria donor lungs preserved in the OCS Lung device (OCS arm) or cold storage at 4°C (control arm). The composite primary effectiveness endpoint was absence of PGD3 within the first 72 h after transplant and 30-day survival in the per-protocol population, with a stringent 4% non-inferiority margin. Superiority was tested upon meeting non-inferiority. The primary safety endpoint was the mean number of lung graft-related serious adverse events within 30 days of transplant. We did analyses in the per-protocol and intention-to-treat populations. This trial is registered with ClinicalTrials.gov, number NCT01630434.

FINDINGS: Between Nov 17, 2011, and Nov 24, 2014, we randomly assigned 370 patients, and 320 (86%) underwent transplantation (n=151 OCS and n=169 control); follow-up was completed in Nov 24, 2016. The primary endpoint was met in 112 (79·4%) of 141 patients (95% CI 71·8 to 85·8) in the OCS group compared with 116 (70·3%) of 165 patients (62·7 to 77·2) in the control group (non-inferiority point estimate -9·1%; 95% CI -∞ to -1·0; p=0·0038; and superiority test p=0·068). Patient survival at day 30 post-transplant was 135 (95·7%) of 141 patients (95% CI 91·0-98·4) in the OCS group and 165 patients (100%; 97·8-100·0) in the control group (p=0·0090) and at 12 months was 126 (89·4%) of 141 patients (83·1-93·9) for the OCS group compared with 146 (88·1%) of 165 patients (81·8-92·8) for the control group. Incidence of PGD3 within 72 h was reported in 25 (17·7%) of 141 patients in the OCS group (95% CI 11·8 to 25·1) and 49 (29·7%) of 165 patients in the control group (22·8 to 37·3; superiority test p=0·015). The primary safety endpoint was met (0·23 lung graft-related serious adverse events in the OCS group compared with 0·28 events in the control group [point estimate -0·045%; 95% CI -∞ to 0·047; non-inferiority test p=0·020]). In the intention-to-treat population, causes of death at 30 days and in hospital were lung graft failure or lung infection (n=2 for OCS vs n=7 for control), cardiac causes (n=4 vs n=1), vascular or stroke (n=3 vs n=0), metabolic coma (n=0 vs n=2), and generalised sepsis (n=0 vs n=1).

INTERPRETATION: The INSPIRE trial met its primary effectiveness and safety endpoints. Although no short-term survival benefit was reported, further research is needed to see whether the reduced incidence of PGD3 within 72 h of a transplant might translate into earlier recovery and improved long-term outcomes after lung transplantation.

FUNDING: TransMedics Inc.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018. PMID: 29650408. doi:10.1016/S2213-2600(18)30136-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。